Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - A cross-sectional study

Cytokine

Volumn 63, Issue 2, 2013, Pages 130-134

  Tewari, Reshu ^a,b   Rajender, Singh ^c   Natu, S M ^a   Goel, Apul ^a   Dalela, Divakar ^a   Goel, M M ^a   Tondon, Pushpa ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b MLN MEDICAL COLLEGE   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Benign prostatic hyperplasia; Cytokines; Obesity; Prostate cancer

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INTERLEUKIN 6; LEPTIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDIAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; WAIST HIP RATIO;

ADIPOKINES; ADIPONECTIN; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HUMANS; INDIA; INTERLEUKIN-6; LEPTIN; MALE; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WAIST-HIP RATIO;

EID: 84878975191     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.04.008     Document Type: Article

References (42)

1. Giri D., Ozen M., Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001, 159:2159-2165.
2. Parkin DM, Whelan SL, Ferlay J, Raymond L, Teppo L, Thomas DB. Cancer incidence in five continents. vol. 8. Lyon:International Agency for Research on Cancer; International Association of Cancer Registries; 2002.
3. Yeole B.B. Trends in the prostate cancer incidence in India. Asian Pac J Cancer Prev 2008, 9:141-144.
4. Zeigler-Johnson C.M., Walker A.H., Mancke B., Spangler E., Jalloh M.M., Bride S., et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002, 54:13-21.
5. Garfinkel L. Overweight and mortality. Cancer 1986, 58:1826-1829.
6. Nomura A.M., Kolonel L.N. Prostate cancer: a current perspective. Epidemiol Rev 1991, 13:200-227.
7. Freeland S.J. Obesity and prostate cancer: a growing problem. Clin Cancer Res 2005, 11:6763-6766.
8. Hsing A.W., Chua S., Gao Y.T., Gentzschein E., Chang L., Deng J., et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001, 93:783-789.
9. Nandeesha H., Koner B.C., Dorairajan L.N., Sen S.K. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006, 370:89-93.
10. Chute C.G., Panser L.A., Girman C.J. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993, 150:85-89.
11. Liu C.C., Wang C.J., Huang S.P., Chou Y.H., Wu W.J., Huang C.H. Relationships between American urological association symptom index, prostate volume, and disease-specific quality of life question in patients with benign prostatic hyperplasia. Kaohsiung J Med Sci 2004, 20:273-278.
12. Housa D., Housova J., Vernerova Z., Haluzik M. Adipocytokines and cancer. Physiol Res 2006, 55:233-244.
13. Pittas A.G., Joseph N.A., Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89:447-452.
14. Tewari R., Rajender S., Natu S.M., Dalela D., Goel A., Goel M.M., et al. Diet, obesity, and prostate health: are we missing the link?. J Androl 2012, 33:763-776.
15. Goktas S., Yilmaz M.I., Caglar K., Sonmez A., Kilic S., Bedir S. Prostate cancer and adiponectin. Urol 2005, 65:1168-1172.
16. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
17. Mohamed-Ali V., Pinkney J.H., Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22:1145-1158.
18. Erin E.K., Jeffrey S.F. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
19. Saglam K., Aydur E., Yilmaz M., Göktaş S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003, 169:1308-1311.
20. 2-terminal kinase. J Biol Chem 2003, 278:42660-42667.
21. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
22. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
23. Freedland S.J. Obesity and prostate cancer: a growing problem. Clin Cancer Res 2005, 11:6763-6766.
24. Dandona P., Weinstock R., Thusu K., Abdel-Rahman E., Aljada A., Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998, 83:2907-2910.
25. Hsing A.W., Gao Y.T., Chua S., Deng J., Stanczyk F.Z. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003, 95:67-71.
26. Way J.M., Görgün C.Z., Tong Q., Uysal K.T., Brown K.K., Harrington W.W., et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001, 276:25651-25653.
27. Baillargeon J., Platz E.A., Rose D.P., Pollock B.H., Ankerst D.P., Haffner S., et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006, 15:1331-1335.
28. Gann P.H. Risk factors for prostate cancer. Rev Urol 2002, 4:S3-S10.
29. Sinha R., Anderson D.E., McDonald S.S., Greenwald P. Cancer risk and diet in India. J Postgrad Med 2003, 49:222-228.
30. Brawer M.K. Screening for prostate cancer. Semin Surg Oncol 2000, 18:29-36.
31. Pelzer A.E., Tewari A., Bektic J., Berger A.P., Frauscher F., Bartsch G., et al. Detection rates and biologic significance of prostate cancer with PSA less than 4.0ng/ml: observation and clinical implications from Tyrol screening project. Urology 2005, 66:1029-1033.
32. Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol 2005, 7:S3-S12.
33. Giovannucci E., Rimm E.B., Liu Y., Leitzmann M., Wu K., Stampfer M.J., et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003, 95:1240-1244.
34. Tewari R., Prabhat P., Natu S.M., Dalela D., Goel A., Goel M.M., et al. Association of benign prostatic hyperplasia (BPH) with the metabolic syndrome (MS) and its components - 'a growing dilemma. J Men's Health 2011, 8:66-71.
35. Schuurman A.G., van den Brandt P.A., Dorant E., Brants H.A., Goldbohm R.A. Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer 1999, 86:1019-1027.
36. Li H., Stampfer M.J., Mucci L., Rifai N., Qiu W., Kurth T., et al. A 25year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010, 56:34-43.
37. Stattin P., Söderberg S., Hallmans G., Bylund A., Kaaks R., Stenman U.H., et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001, 86:1341-1345.
38. Shariat S.F., Andrews B., Kattan M.W., Kim J., Wheeler T.M., Slawin K.M. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001, 58:1008-1015.
39. Azevedo A., Cunha V., Teixeira A.L., Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2011, 2:384-396.
40. Ara T., Declerck Y.A. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010, 46:1223-1231.
41. Degeorges A., Tatoud R., Fauvel-Lafeve F., Podgorniak M.P., Millot G., de Cremoux P., et al. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996, 68:207-214.
42. Cabrespine A., Bay J.O., Verrelle P., Morel L. Interleukin-6 implication in prostate cancer. Bull Cancer 2007, 94:F29-F34.